## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.8% below STRENGTH zone (4.0-10.0%); PEG 1.72 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($73.25)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Why Henry Schein (HSIC) Stock Is Up Today**
- Source: The Globe and Mail | 20251210T060833 | Somewhat-Bullish | Relevance: 100%
- Shares of Henry Schein (NASDAQ:HSIC), a dental and medical products company, rose 2.8% after Barclays initiated coverage with an 'Overweight' rating and an $86 price target. The company also announced an extension of its strategic partnership with KKR. This positive news follows a previous stock gain related to hopes for an interest rate cut from the Federal Reserve.

**2. Westwood Holdings Group Inc. Invests $20.63 Million in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251215T140618 | Somewhat-Bullish | Relevance: 100%
- Westwood Holdings Group Inc. has acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC) valued at approximately $20.63 million, purchasing 282,420 shares in the second quarter. Other institutional investors also adjusted their holdings in Henry Schein, with several analysts offering price target adjustments and ratings from "buy" to "hold." The company's stock performance shows a market cap of $9.01 billion and a consensus "Hold" rating from analysts with an average price target of $76.92.

**3. Ilex Capital Partners UK LLP Takes Position in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251212T210805 | Bullish | Relevance: 100%
- Ilex Capital Partners UK LLP has taken a significant new position in Henry Schein, Inc. (NASDAQ:HSIC) during the second quarter, acquiring 17,402 shares valued at approximately $1.27 million. Other institutional investors like Norges Bank, M.D. Sass, and Schroder Investment Management Group also increased their stakes, leading to institutional investors holding 96.62% of the stock. Analysts have a mixed outlook with a consensus "Hold" rating and a $76.92 price target, despite the company exceeding Q3 earnings expectations and providing strong FY2025 EPS guidance.

**4. Did Henry Schein’s (HSIC) Expanded vVARDIS Deal Quietly Recast Its Minimally Invasive Dental Strategy?**
- Source: Simply Wall Street | 20251212T093112 | Bullish | Relevance: 100%
- Henry Schein recently expanded its exclusive U.S. distribution agreement with vVARDIS for the Curodont Repair Fluoride Plus treatment, strengthening its position in minimally invasive dentistry. This move, alongside the extended KKR partnership, aims to integrate new offerings and drive efficiency. Henry Schein expects significant revenue and earnings growth by 2028, with its fair value aligning with its current price, though some analysts see potential for higher valuation.

**5. Did Henry Schein’s (HSIC) Expanded vVARDIS Deal Quietly Recast Its Minimally Invasive Dental Strategy?**
- Source: Simply Wall Street | 20251212T090758 | Somewhat-Bullish | Relevance: 100%
- Henry Schein (HSIC) has expanded its agreement with vVARDIS, gaining exclusive U.S. distribution rights for the drill-free Curodont Repair Fluoride Plus treatment. This move strengthens Henry Schein's position in minimally invasive dentistry and aligns with its broader strategy focusing on technology integration and cost savings, supported by a continued partnership with KKR. The company is projected to achieve $14.4 billion in revenue and $614.4 million in earnings by 2028, with its fair value currently estimated at $77.00.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +5.9% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.72 elevated, pricing in significant growth expectations. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 6.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.72 |
| Forward P/E | 14.5 |
| Current P/E | 15.6 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.1% to 3.8% (+5.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.2pp (needs >4.0% for momentum thesis). MRS_5 at 3.2% confirms short-term momentum alignment. AM_20 at 4.2% shows strong absolute momentum above own 20MA. Outperforming sector by 4.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.80% (CS: 68) | Neutral |
| RSI_14 | 66.7 | Neutral |
| MACD Histogram | 0.08 | Bullish |
| vs SMA20 | 1.042x | Above |
| vs SMA50 | 1.109x | Above |
| vs SMA200 | 1.106x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $76.55
- **Stop Loss:** $73.25 (4.3% risk)
- **Target:** $79.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 303
- **Position Value:** $23,194.65
- **Portfolio %:** 23.19%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*